Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

Published on January 6, 2009   54 min

Other Talks in the Therapeutic Area: Oncology

Hide

Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

Embed in course/own notes